Youssef Mohamed A, Al-Sharif Hisham, McGrath Brian T, Picken Maria M, Le Poole I Caroline
Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, United States.
Department of Pathology, The University of Texas Medical Branch, Galveston, TX, United States.
Front Immunol. 2025 Jun 24;16:1593960. doi: 10.3389/fimmu.2025.1593960. eCollection 2025.
Immunotherapy has shown significant potential for treating malignancies. Not yet widely considered is the opportunity to employ immunotherapy for the treatment of benign tumors. By focusing on targetable antigens expressed following specific genetic changes associated with individual benign tumors, immunotherapy may provide an effective approach to benign tumor treatment, circumventing the need for more conventional surgery. Immunotherapies can specifically recognize and target tumor cells, which could be especially beneficial for benign tumors given the extended timeframe available for treatment. Thus, benign tumors, offering a greater window of opportunity for treatment and a relatively stable phenotype associated with a limited mutation burden, can derive great benefit from immunotherapeutic approaches targeting antigens uniquely associated with each condition.
免疫疗法在治疗恶性肿瘤方面已显示出巨大潜力。然而，利用免疫疗法治疗良性肿瘤的机会尚未得到广泛关注。通过聚焦于与个体良性肿瘤相关的特定基因变化后表达的可靶向抗原，免疫疗法可能为良性肿瘤治疗提供一种有效方法，从而无需进行更为传统的手术。免疫疗法能够特异性识别并靶向肿瘤细胞，鉴于有更长的治疗时间框架，这对良性肿瘤可能特别有益。因此，良性肿瘤具有更大的治疗机会窗口以及与有限突变负担相关的相对稳定表型，可从针对每种情况独特相关抗原的免疫治疗方法中获益良多。
